Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-3 (cancelled).

4 (currently amended). A substantially pure polypeptide comprising the sequence identified as SEQ ID NO:1.

5 (previously presented). The polypeptide according to claim 4 with a molecular mass of about 20k.

6-21 (cancelled).

22 (currently amended). A pharmaceutical composition comprising the polypeptide of claim ~~1~~ 50.

23-27 (cancelled).

28 (currently amended). A method for treating patients deficient in the activity of MASP-2 by administering to the patient the polypeptide of claim ~~1~~ 50.

29-45 (cancelled).

46 (currently amended). A substantially pure polypeptide consisting of the sequence of SEQ ID NO:~~1 or~~ 2, or of the sequence defined by position 16 to position 686 of SEQ ID NO:2.

47 (currently amended). A substantially pure polypeptide comprising ~~a~~ an amino acid sequence at least 85% identical to the sequence defined by position 16 to position 686 of SEQ ID NO:2, wherein said polypeptide has at least one of the following activities

i) cleavage of C4 and activation of the complement ~~MASP-2 activity~~ in an in vitro assay for MBLectin complement pathway function; or

ii) serine protease activity; or

iii) mannan-binding lectin (MBL) associating activity.

48 (cancelled).

49 (currently amended). The polypeptide according to claim 47 in which the polypeptide comprises a sequence at least 90% identical to the sequence defined by position 16 to position 686

of SEQ ID NO:2.

50 (currently amended). A substantially pure ~~The~~ polypeptide ~~according to claim 47, in~~ which the polypeptide comprises ~~a~~ an amino acid sequence at least 95% identical to the sequence defined by position 16 to position 686 of SEQ ID NO:2, wherein said polypeptide has the following activities

i) cleavage of C4 and activation of the complement in an in vitro assay for MBLectin complement pathway function; and

ii) mannan-binding lectin (MBL) associating activity.

51 (currently amended). The polypeptide according to claim 47, in which the polypeptide comprises a sequence at least 98% identical to the sequence defined by position 16 to position 686 of SEQ ID NO:2.

52 (currently amended). The polypeptide according to claim 47, in which the polypeptide comprises a sequence at least 99% identical to the sequence defined by position 16 to position 686 of SEQ ID NO:2.

53 (currently amended). The polypeptide according to claim 47, in which differences between the polypeptide sequence and residues 16 to 686 of SEQ ID NO:2 are limited to conservative substitutions.

54 (currently amended). The polypeptide according to claim ~~48~~ 50 in which differences between the polypeptide sequence and SEQ ID NO:1 are limited to conservative substitutions.

55-56 (cancelled).

57 (new). A substantially pure polypeptide comprising the amino acid sequence of position 16 to position 686 of SEQ ID NO:2.

58 (new). The polypeptide of claim 4, consisting of the sequence of SEQ ID NO:1.

59 (new). The polypeptide of claim 50 where said polypeptide is bound by a monoclonal antibody which binds mature MASP-2.

60 (new). The polypeptide of claim 50 which comprises a contiguous 100 amino acid sequence which is completely identical to a sequence of 100 contiguous amino acids within the sequence from position 16 to position 686 of SEQ ID NO:2.

61 (new). The polypeptide of claim 50 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

62 (new). The polypeptide of claim 51 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

63 (new). The polypeptide of claim 52 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

64 (new). The polypeptide of claim 54 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

65 (new). The polypeptide according to claim 51 in which differences between the polypeptide sequence and SEQ ID NO:1 are limited to conservative substitutions.

66 (new). The polypeptide according to claim 52 in which differences between the polypeptide sequence and SEQ ID NO:1 are limited to conservative substitutions.

67 (new). The polypeptide of claim 65 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

68 (new). The polypeptide of claim 66 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

69 (new). The polypeptide of claim 53 which comprises a sequence which, when aligned with SEQ ID NO:2, is identical to SEQ ID NO:2 at each position of SEQ ID NO:2 which is marked with an asterisk in Fig. 2 because it is a conserved residue position in MASP-2, MASP-1, Clr and Cls.

70 (new). A substantially pure polypeptide which is obtainable from human plasma by affinity chromatography on mannan- and N-acetyl-glucosamine derivatized sepharose beads in the presence of a calcium salt, has an apparent molecular weight of 52 kDa when analyzed by SDS-PAGE, and has the following activities

i) cleavage of C4 and activation of the complement in an in vitro assay for MBLectin complement pathway function; and

ii) mannan-binding lectin (MBL) associating activity.

71(new). A substantially pure polypeptide which is obtainable from human plasma by affinity chromatography on mannan- and N-acetyl-glucosamine derivatized sepharose beads in the presence of a calcium salt, has an apparent molecular weight of 52 kDa when analyzed by SDS-PAGE, comprises

(1) a sequence identical to the sequence defined by positions 16 to 56 of SEQ ID NO:2,

(2) a sequence identical to the sequence defined by positions 108 to 134 of SEQ ID NO:2,

(3) a sequence identical to the sequence defined by positions 377 to 388 of SEQ ID NO:2, and

(4) a sequence identical to the sequence defined by positions 410 to 417 of SEQ ID NO:2,

and has the following activities

i) cleavage of C4 and activation of the complement in an

in vitro assay for MBLectin complement pathway function; and

ii) mannan-binding lectin (MBL) associating activity.